PAVMED INC (PAVM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$1.66-8.79%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · PAVM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 747.5% |
| Our one-year growth estimate | diamond | -55.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 803.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 29 industry peers
PAVM — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-10-22
Material Modification to Rights of Security Holders. The information included in
Why it matters: Lucid entered a preferred stock sale agreement on October 21. Its terms and any cash raised may affect Lucid's funding and share count.
Watch forA filing states the sale closed, gives the cash raised, and shows no change to the stated terms.
Also watch forA filing reports that the sale did not close, terms changed, or more shares may be issued than first stated.
Why it matters: Lucid reported $1.3 million in first-quarter revenue and $1.5 million in the second. Further growth would show that demand is building.
Supportive ifAt the next report, EsoGuard revenue is above $1.5 million for the quarter.
Worry ifAt the next report, EsoGuard revenue is $1.5 million or lower.
Why it matters: PAVmed reported $3.8 million in cash at June 30, 2026, and steady cash use. A stock sale could add cash but also issue shares.
Watch forA filing shows new cash from stock sales, while quarterly cash use falls below $2.6 million.
Also watch forA filing shows stock sales, but cash use stays at or above $2.6 million and cash falls from $3.8 million.
Why it matters: A planned FDA meeting in late 2026 could help set the next steps for PortIO. Its first-in-human results showed device patency in all patients.
Supportive ifPAVmed requests an FDA meeting in the fourth quarter of 2026, as planned.
Worry ifPAVmed reports the request was not made in the fourth quarter, or says FDA feedback blocks the planned path.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$365 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $992 loss on $10,000 · 9.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,622 loss on $10,000 · 86.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.